57 results about "Vitamin D deficiency osteomalacia" patented technology

The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. for mending broken bone or for prophylaxis or therapy of metabolic bone diseases such as osteoporosis and osteomalacia and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity in vivo.

Disclosed are compositions and methods for preventing, inhibiting, reducing and treating conditions and diseases associated with abnormal bone resorption in mammals, including for example osteoporosis. Embodiments of compositions of the invention comprise a pharmaceutically effective amount of alendronate and vitamin D3 suitable for once-weekly dosing. Compositions and methods of the invention provide vitamin D nutrition during bisphosphonate treatment to facilitate normal bone formation and mineralization while minimizing the occurrence of or potential for the complications associated with vitamin D insufficiency, such as hypocalcaemia and osteomalacia. Also disclosed are methods for manufacturing compositions of the present invention, for measuring stability and degradation of those compositions, and for measuring blood plasma levels of vitamin D.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The key function of TNAP in bone is degradation of PPi to remove this mineralization inhibitor and provide free phosphate for apatite deposition. PC-1 is a direct antagonist of TNAP function. ANK also antagonizes TNAP-dependent matrix calcification. Specifically, the activity of PC-1 inhibits initial MV apatite deposition, but ANK inhibits propagation of apatite outside the MVs. Furthermore, loss of function of the two distinct skeletal TNAP antagonists, PC-1 and ANK, ameliorates TNAP deficiency-associated osteomalacia in vivo. Conversely, the hyperossification associated with both PC-1 null mice and ANK-deficient (ank / ank) mice is ameliorated by deficiency of TNAP in vivo.

Composition and method for preventing or treating abnormal bone resorption in mammals, the composition characterized as containing, a supplementary effective amount of a non-activated metabolite of vitamin D2 and / or D3 and a pharmaceutically effective amount of bisphosphonate to provide vitamin D nutrition during treatment to facilitate normal bone formation and mineralization, while minimizing the occurrence of or potential for the complications associated with vitamin D insufficiency, such as hypocalcemia and osteomalacia. The method of preventing or treating may be further characterized by concomitantly administering the components simultaneously or alternately at dosing intervals selected from once-weekly, twice-weekly, bi-weekly, monthly, and bimonthly.

Disclosed are methods of inhibiting bone resorption and / or promoting bone formation using GLP-2 and related Compounds. The invention has a wide spectrum of important uses including hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilisation or sex hormone deficiency, osteomalacia, hyperostosis and osteopetrosis.

The invention relates to a food composition containing Maca and saussurea involucrata culture and an application thereof. The composition is prepared by the following raw materials in percentage by weight: 50-90% of maca, 10-50% of saussurea involucrata culture and 0-0.02% of vitamin K2. The food composition is used for preventing and treating rheumatism, arthritis, osteomalacia, osteoporosis and osteoporotic fracture. The food composition has a kidney regulating function and body building and bone benefiting functions, can strengthen the muscle and bone motion capability, and can stimulate the active ingredients of tissue cells. The food composition regulates internal secretion, strengthens an immune function and improves chronic fatigue syndrome, depressive disorder and osteoporotic syndrome.

The invention provides methods for treating or preventing bone degenerative disorders. The disorders treated or prevented include, for example, osteopenia, osteomalacia, osteoporosis, osteomyeloma, osteodystrophy, Paget's disease, osteogenesis imprerfecta, and bone degenerative disorders associated with chronic renal disease, hyperparathyroidism, high levels of endogenous thyrotropin, and long-term use of corticosteroids. The disclosed therapeutic methods include administering to a mammal a TSHR agonist in an amount effective to: (1) treat or prevent a bone degenerative disorder; (2) slow bone deterioration; (3) restore lost bone; (4) stimulate new bone formation; and / or (5) maintain bone mass and / or bone quality. TSHR agonists such as thyrotropin and its modified forms are provided along with other compounds, such as anti-resorptive agent and bone metabolic agents.

The invention discloses a medicine for treating bovine osteomalacia, comprising the following traditional Chinese medicine raw materials: 300 of astragalus root, 150 of radix codonopsis pilosulae, 150of white atractylodes rhizome, 100 of angelica, 300 of eucommia bark, 500 of psoralea corylifolia, 300 of waras, 600 of fossilia ossis mastodi, 100 of officinal magnolia, 90 of villous anomum, 60 oftsaoko cardamon, 800 of raw hawthorn, 500 of dog bone, 300 of tuckahoe and 500 of osseocolla. The invention has the advantages of quick curative effect, high cure rate, no toxic or side effect, unlikeliness of relapse, no medicine harm, low cost and the like. The effective rate of treating bovine osteomalacia can reach 100%, and the cure rate is about 98%.

The invention discloses a traditional Chinese medicine preparation for treating hyperosteogeny and lumbar disc herniation and a preparation method thereof, belonging to the technical field of traditional Chinese medicines. Choose 13 traditional Chinese medicines such as Angelica, Dipsacus, Rhizoma Drynaria, Gastrodia elata, Dried Blood, White Flower Snake, Duhuo, Panax notoginseng, Pueraria lobata, Pangolin, Saffron, Cornus officinalis, and worms to wash, dry or dry, and then pulverize 100- Sieve through a 120-mesh sieve, stir and mix evenly to form a powder; or make capsules, water pills, pasted pills, and honeyed pills. The traditional Chinese medicine preparation has the functions of strengthening body and expelling wind, nourishing dampness and dispelling cold, nourishing liver and kidney, promoting blood circulation and removing blood stasis, and dredging meridians. Soften the proliferated bone of the patient, eliminate joint pain and numbness; restore nerves, physique, and functions, and achieve complete rehabilitation.

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.

The invention relates to a food composition containing Maca and saussurea involucrata culture and an application thereof. The composition is prepared by the following raw materials in percentage by weight: 50-90% of maca, 10-50% of saussurea involucrata culture and 0-0.02% of vitamin K2. The food composition is used for preventing and treating rheumatism, arthritis, osteomalacia, osteoporosis and osteoporotic fracture. The food composition has a kidney regulating function and body building and bone benefiting functions, can strengthen the muscle and bone motion capability, and can stimulate the active ingredients of tissue cells. The food composition regulates internal secretion, strengthens an immune function and improves chronic fatigue syndrome, depressive disorder and osteoporotic syndrome.

19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit significant activity in mobilization of bone, making them therapeutic agents for the treatment or prophylaxis of osteoporosis, osteomalacia, osteopenia, renal osteodystrophy and hypoparathyroidism.

Provided is a compound showing a bone formation promoting action (and / or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt:[wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit significant activity in mobilization of bone, making them therapeutic agents for the treatment or prophylaxis of osteoporosis, osteomalacia, osteopenia, renal osteodystrophy and hypoparathyroidism.

The invention provides methods for treating or preventing bone degenerative disorders. The disorders treated or prevented include, for example, osteopenia, osteomalacia, osteoporosis, osteomyeloma, osteodystrophy, Paget's disease, osteogenesis imperfecta, and bone degenerative disorders associated with chronic renal disease, hyperparathyroidism, and long-term use of corticosteroids. The disclosed therapeutic methods include administering to a mammal an inhibitor of GDF-9 or BMP-15 in an amount effective to: (1 ) treat or prevent a bone degenerative disorder; (2) slow bone deterioration; (3) restore lost bone; (4) stimulate new bone formation; and / or (5) maintain bone mass and / or bone quality. The invention also provides methods for administering a GDF-9 agonist or a BMP-15 agonist to treat a bone disorder characterized by increased bone density or mass.

The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.

The topical composition with Vitamin D3 includes Vitamin D3, one or more aromatic oils, and aloe vera gel. Vitamin D3 is soluble in aromatic oils, and aloe vera gel enables transport through the stratum corneum so that the composition may be used for fulfilling daily requirements, treatment of bone conditions, such as rickets and osteomalacia, and supportive therapy in osteopenia and osteoporosis. The aromatic oil may be a citric acid extract (e.g., orange oil extracted from orange peels), lavender oil, or any other aromatic oil in which Vitamin D3 is soluble. Optionally, the composition may include excipients, such as a permeability enhancer (e.g., glycerine and water), a preservative (e.g., a carbomer, methyl paraben, EDTA, or the like), or other additives that do not affect the active ingredients. The composition is preferably formulated as a cream or emulsion.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention relates to a tap water instant drinking machine, which comprises a shell and two or more water tanks arranged inside the shell. The inside of the shell is provided with a filtering device, which is in seal connection with the water tanks through a water inlet pipe. The water inlet pipe is equipped with a permanent magnet and a high-frequency electromagnetic wave sterilizer. The instant drinking machine is equipped with a plurality of water tanks, and alternate use of the water tanks is controlled by water inlet electromagnetic valves and water outlet electromagnetic valves so as to ensure continuous water supply of the water tanks. When one water tank is in service, the other water tanks store tap water and ultraviolet sterilization is carried out, thus guaranteeing sufficient water sources and the sterilization time of the water tanks. The filtering device is internally provided with pp cotton and activated carbon. Overcoming the defects in traditional reverse osmosis membranes, the instant drinking machine provided by the invention removes the impurities in water and does not cause the problems of osteoporosis of the elderly, children osteomalacia and intelligence quotient dysplasia.

The invention discloses a comprehensive feed for bamboo rats. The comprehensive feed comprises the following ingredients: corn kernels, cut fresh phyllostachys pubescens slices, fresh pennisetum sinese roxb stems and blackened swallowwort roots. In the field of culture of bamboo rats, due to the existing feed, the bamboo rats easily have diarrhea, osteomalacia and other diseases, the drug and feed input expenses are increased, meanwhile, the bamboo rats need to change teeth every year, and have high fat content, loose meat, and poor taste, and the excrement particles are large. The comprehensive feed just solves the problems, through the comprehensive use of the ingredients, the nutrition needed by the bamboo rats can be effectively supplemented, meanwhile, the raw materials are easily available, the feed is easy to prepare and the cost is relatively low.

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention discloses a chromium containing meat duck feed, including main materials and additives. The main materials comprise 50-60 parts of corn, 20-30 parts of cereal chaff, 20-30 parts of wheat bran, 50-60 parts of rice bran, 40-50 parts of rye, 10-20 parts of broken rice and 4-5 parts of edible salt. The additives comprise 15-20 parts of pine needle powder, 6-9 parts of kelp powder, 1-5 parts of egg shell powder, 5-6 parts of citric acids, 5-6 parts of multivitamins and 0.8-1.5 parts of yeast chromium. The chromium containing meat duck feed can improve feed palatability, increase appetite, improve feed intake, promote the growth of meat duck, increase the meat duck weight gain speed, and shorten the time of slaughter. The addition of high dose of VA and VE can meet the need of meat duck for vitamins under intensive rearing conditions, and the meat duck feed can improve organism immune function, enhance resistance to disease and stress, improve meat quality, increase VD3 content, and effectively prevent the occurrences rickets, osteomalacia and leg diseases.

The invention provides methods for treating or preventing bone degenerative disorders. The disorders treated or prevented include, for example, osteopenia, osteomalacia, osteoporosis, osteomyeloma, osteodystrophy, Paget's disease, osteogenesis imperfecta, and bone degenerative disorders associated with chronic renal disease, hyperparathyroidism, and long-term use of corticosteroids. The disclosed therapeutic methods include administering to a mammal an inhibitor of GDF-9 or BMP-15 in an amount effective to: (1) treat or prevent a bone degenerative disorder; (2) slow bone deterioration; (3) restore lost bone; (4) stimulate new bone formation; and / or (5) maintain bone mass and / or bone quality. The invention also provides methods for administering a GDF-9 agonist or a BMP-15 agonist to treat a bone disorder characterized by increased bone density or mass.

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.